A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).

Adrienne G. Waks,Tanya Keenan,Tianyu Li,Nabihah Tayob,Gerburg M. Wulf,Edward T. Richardson,Elizabeth A. Mittendorf,Beth Overmoyer,Ian E. Krop,Eric P. Winer,Eliezer M. Van Allen,Judith Agudo,Sara M. Tolaney

A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).

2020

Adrienne G. Waks
Tanya Keenan
Tianyu Li
Nabihah Tayob
Gerburg M. Wulf
Edward T. Richardson
Elizabeth A. Mittendorf
Beth Overmoyer
Ian E. Krop
Eric P. Winer
Eliezer M. Van Allen
Judith Agudo
Sara M. Tolaney

1046Background: Preclinical evidence suggests treatment (tx) with T-DM1 plus an anti-PD1 antibody triggers antitumor immunity. We conducted a phase 1 trial to determine the safety and explore the e...

Keywords:

Oncology
Trastuzumab emtansine
Internal medicine
Breast cancer
Pathology
Pembrolizumab
Medicine
Antibody
antitumor immunity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations